Bronte G, Galvano A, Cicero G, Passiglia F, Rolfo C, Bazan V, Russo A
Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy.
Phase I Unit-Early Clinical Trials, University of Antwerp, Edegem, Belgium.
Drugs Today (Barc). 2014 Sep;50(9):613-21. doi: 10.1358/dot.2014.50.9.2207198.
The inhibition of the mechanisms of tumor neo-angiogenesis represents a milestone that in the last 10 years has seen the advent of numerous molecules to target action against the vascular endothelial growth factor (VEGF). More recently, new molecules have been developed that inhibit tumor spread by the blockade of specific VEGF receptors (VEGFRs), thereby preventing the binding of a ligand to its receptor and the cascade of proliferative events downstream. Ramucirumab is a fully humanized IgG1 monoclonal antibody that performs its action by blocking the isoform 2 of the VEGF receptor (VEGFR-2). Numerous preclinical and clinical studies have demonstrated its activity in several solid tumors, demonstrating a remarkable efficacy in terms of progression-free survival and overall survival in addition to a favorable toxicity profile. This review analyzes in detail the role of ramucirumab in the treatment of advanced gastric and gastroesophageal junction cancers.
肿瘤新生血管生成机制的抑制是一个里程碑，在过去10年里，出现了众多针对血管内皮生长因子（VEGF）发挥作用的分子。最近，又开发出了新的分子，它们通过阻断特定的VEGF受体（VEGFRs）来抑制肿瘤扩散，从而防止配体与其受体结合以及下游的增殖事件级联反应。雷莫西尤单抗是一种完全人源化的IgG1单克隆抗体，它通过阻断VEGF受体2（VEGFR-2）的同种型2发挥作用。众多临床前和临床研究已证明其在多种实体瘤中的活性，除了具有良好的毒性特征外，在无进展生存期和总生存期方面也显示出显著疗效。本综述详细分析了雷莫西尤单抗在晚期胃癌和胃食管交界癌治疗中的作用。
